Recent

% | $
Quotes you view appear here for quick access.

Hemispherx Biopharma, Inc. Message Board

johnnyd_79902 68 posts  |  Last Activity: Jun 24, 2016 5:10 PM Member since: May 13, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • (It appears there is a push for Ampligen)

    Cort Johnson
    June 23, 2016

    Ampligen has been in the FDA pipeline for so many years that it almost seems like a mirage at this point. The ME/CFS community has been praying, hoping, believing that Ampligen will be its first FDA approved drug for over twenty years. For a lot of people that hope may have died, but the drug has gotten new life recently.
    .
    .
    .
    Conclusion

    While there were some problems with the trials the drug did meet several important endpoints including increasing time on a treadmill and increased oxygen utilization. It should be noted that Ampligen has tried to move the needle on probably the most difficult factor of all to budge in ME/CFS: oxygen utilization during exercise.

    Any drug providing clinical benefit to 30-40% of a population which has no approved drugs should be a slam dunk. (Less effective drugs have been readily approved in other illnesses). Hopefully, with new leadership, Hemispherx’s twenty plus year journey to bring Ampligen to market will end successfully, and the ME/CFS community will finally get its first drug approved.

  • johnnyd_79902 johnnyd_79902 Jun 24, 2016 12:07 PM Flag

    Francis Collins will think your question is quite stupid, better think of another one for him.

  • johnnyd_79902 johnnyd_79902 Jun 24, 2016 11:07 AM Flag

    Don;t like my answer? Maybe you should ask Francis Collins - he's the one considering an ampligen trial.

    In a recent interview, Collins described the range of possibilities under discussion. “They’re talking about everything from basic science – the metabolome, microbiome, immune system, imaging – to clinical trials for promising approaches, including Ampligen and Rituximab,” Dr. Collins said.

    Let us know what Collins says you pofs.

  • johnnyd_79902 johnnyd_79902 Jun 24, 2016 9:34 AM Flag

    Why would I explain anything to a hedgie?

    boris_badenov192
    2 posts | Last Activity: 1 minute 13 seconds ago
    Member since: Jun 17, 2016

  • meaction.net/2016/06/23/help­us­ask­nih­to­fund­an­ampligen­trial­today/
    By Courtney Alexander Miller
    NIH is asking the ME/CFS community what future research should be done. Below is a request to have NIH fund clinical trials for ME/CFS starting with Ampligen, as the only medication close to approval in the FDA pipeline. If you want to add your name to this request, the deadline is midnight Thursday, 6/23. Some organizations and dozens of patients have signed onto it, but we would like to show NIH how important treatment studies are to our community. The text of our response is below.

    To join the letter, email your name, years ill, and state to Courtney Miller at courtneymiller999@gmail.com and tell us you wish to join the Ampligen letter.

    Note: this is separate from the RFI as produced by the survey, and has been undertaken by Courtney Miller rather than by #MEAction as an entity.

    For additional information about Ampligen in ME/CFS, visit the MEpedia page on Ampligen.

    Response to Notice Number: NOT­NS­16­024
    Request for Information: Soliciting Input for New Research Strategies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

    NIH should immediately fund a small, well­powered clinical trial to demonstrate efficacy of Ampligen for treatment of ME/CFS patients or a subset thereof, soliciting applications in 2016 from clinicians experienced in treating patients with Ampligen. The trial should be double­blind, placebo­controlled, demonstrating efficacy and characterizing responders.

    Additionally, NIH should solicit applications for new clinical trials of promising medications for treatment of ME/CFS, such as rituximab, anti­virals, monoclonal antibodies, and cross­purposed treatments from similar diseases like Multiple Sclerosis.

    Supporting discussion:
    ------------
    Google the subject for the supporting discussion

  • Wow, Hello AstraZenica???, we have the solution to your problem with flumist.!!!

    Possibly another transaction point JJ?

  • Reply to

    Tidy up the house.....

    by hebguru49307 Jun 22, 2016 12:40 PM
    johnnyd_79902 johnnyd_79902 Jun 23, 2016 2:58 PM Flag

    Well, clearing the slate on the company as a whole, will not hurt any type of transaction, imo :) It appears the main transaction types now are Ampligen for CFS, Ampligen for Cancer and Alferon manufacturing.

    Cancer is a real wild card here - HEB is very proud about something, I'm dying to hear from Kalinski - that could entice a big to take on both CFS and manufacturing. Ah the possibilities.

    Kiani oversaw the state of the art alferon manufacturing re-do - but he is now gone - so that opens the way for a big, with even more expertise. I'd think a big would be VERY interested in that plant. It is incredible.

  • Reply to

    Tidy up the house.....

    by hebguru49307 Jun 22, 2016 12:40 PM
    johnnyd_79902 johnnyd_79902 Jun 23, 2016 1:52 PM Flag

    I think part of the tidying up is a gov't requirement that HEB do everything it can to attract a private partner... before the NIH can justify spending millions on an NIH sponsored Ampligen trial. Taxpayers money after all. Very interested to see how it plays out.

  • johnnyd_79902 johnnyd_79902 Jun 22, 2016 3:27 PM Flag

    Especially for you hedgies.... lol

  • Reply to

    Email campaign to NIH to study Ampligen

    by johnnyd_79902 Jun 22, 2016 12:55 PM
    johnnyd_79902 johnnyd_79902 Jun 22, 2016 2:54 PM Flag

    What a big fat liar.

    The Trans-NIH ME/CFS Working Group will review the comments about ME/CFS research that they receive from the public and potentially use this information to direct current and future research.

    rituximab appears much LESS promising.

  • Reply to

    Email campaign to NIH to study Ampligen

    by johnnyd_79902 Jun 22, 2016 12:55 PM
    johnnyd_79902 johnnyd_79902 Jun 22, 2016 1:08 PM Flag

    This is the NIH ASKING for your input an RFI (Request For Information)

    On May 24th, the National Institutes of Health (NIH) released the document Request for Information: Soliciting Input for New Research Strategies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). An RFI, or Request for Information is “critical for identification and consideration of research areas and topics to be included in future efforts.” The Trans-NIH ME/CFS Working Group will review the comments about ME/CFS research that they receive from the public and potentially use this information to direct current and future research.

  • OK longs, another chance for you to be pro-active. This is on #meactions wiki if you want to search.

    ---
    Hemispherx Biopharma has written this email for people to copy and paste asking the NIH to study Ampligen in a clinical trial. Feel free to change or personalize. (Do not include any personal information you wish to remain confidential.)

    Must be submitted by Friday, June 24, 2016.

    Email Address
    Please send to: MECFSRFI@mail.nih.gov

    Subject line
    Subject line: RFI response: Research Needs/Opportunities ME/CFS

    Body of Email
    NIH should fund and direct a Phase IV clinical trial of Ampligen for the treatment of ME/CFS.

    ME/CFS is a severely debilitating, chronic and complex disease. Considered a public health crisis, it is a critical unmet medical need with a severe lack of funding; we recommend a Phase IV study be conducted by the NIH granted under a conditional approval by the FDA and in collaboration with the support of the sponsor. The recommendation fulfills NIH/FDA’s goal to speed new treatments to patients announced in 2010*.

    • A description of the need or opportunity Currently there is no approved drug therapies for ME/CFS, however Ampligen provides a most unique opportunity to advance a treatment, further understand the disease and open the regulatory doors for other pharmaceutical companies to pursue drug development. No other therapy has advanced this far in the FDA pipeline. New drug therapies entering the pipeline may take another decade before approval. FDA regulations permit conditional approval of drugs and their collaborative initiative with NIH offers the pathway conduct the study.

    • A scientific rationale and potential health impact

  • Reply to

    Tidy up the house.....

    by hebguru49307 Jun 22, 2016 12:40 PM
    johnnyd_79902 johnnyd_79902 Jun 22, 2016 12:50 PM Flag

    My guess: They expect company. The question is, Gov't company? or Private company? 8^)

  • Reply to

    Trading......what Im watching today

    by hebguru49307 Jun 21, 2016 10:12 AM
    johnnyd_79902 johnnyd_79902 Jun 22, 2016 9:41 AM Flag

    Looks like a little fight this morning.

  • johnnyd_79902 johnnyd_79902 Jun 20, 2016 9:03 PM Flag

    ROFL

  • Reply to

    Trading today......

    by hebguru49307 Jun 20, 2016 6:42 PM
    johnnyd_79902 johnnyd_79902 Jun 20, 2016 9:02 PM Flag

    ROFL

  • johnnyd_79902 johnnyd_79902 Jun 20, 2016 8:16 PM Flag

    Iraj Kiani is Carter's wife???? William Carter will be surprised to hear that,

    i1dumbo is a complete idiot.

  • Reply to

    Duck's Quacks

    by marin655aa Jun 11, 2016 8:10 PM
    johnnyd_79902 johnnyd_79902 Jun 13, 2016 9:19 PM Flag

    LOL I don't think so.

  • johnnyd_79902 johnnyd_79902 Jun 6, 2016 11:44 AM Flag

    LOL, the hedgies are too funny.... and so transparent.

    It's no secret that Carter was reluctant to take on big partners - getting burned by Dupont. It's no secret that Carter wanted HEB to be the next Pfizer and do everything in house - Equels said as much recently.

    And now it's no secret that big partners are interested in HEB.

    Too bad for you hedgies. lol

  • johnnyd_79902 johnnyd_79902 Jun 6, 2016 9:51 AM Flag

    "This 'belt and suspenders’ approach is intended to provide comfort to future development partners that any rights Dr. Carter may have had in our intellectual property portfolio have been fully assigned by Dr. Carter."

HEB
0.1155-0.0045(-3.75%)Jun 24 4:02 PMEDT